Callan Family Office LLC Grows Stake in Hims & Hers Health, Inc. $HIMS

Callan Family Office LLC increased its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 70.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,004 shares of the company’s stock after purchasing an additional 14,086 shares during the quarter. Callan Family Office LLC’s holdings in Hims & Hers Health were worth $1,695,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Northern Trust Corp grew its position in shares of Hims & Hers Health by 19.5% during the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock worth $71,969,000 after purchasing an additional 397,310 shares in the last quarter. Yong Rong HK Asset Management Ltd grew its holdings in Hims & Hers Health by 41.2% during the 1st quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company’s stock valued at $70,920,000 after buying an additional 700,100 shares in the last quarter. Nuveen LLC purchased a new position in Hims & Hers Health during the 1st quarter valued at approximately $58,403,000. BIT Capital GmbH grew its holdings in Hims & Hers Health by 7.4% during the 1st quarter. BIT Capital GmbH now owns 1,642,493 shares of the company’s stock valued at $48,536,000 after buying an additional 112,949 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in Hims & Hers Health by 1.2% during the 1st quarter. Bank of New York Mellon Corp now owns 1,260,292 shares of the company’s stock valued at $37,242,000 after buying an additional 15,339 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Activity at Hims & Hers Health

In related news, insider Patrick Harrison Carroll sold 60,000 shares of the business’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the completion of the transaction, the insider owned 169,940 shares in the company, valued at $9,105,385.20. The trade was a 26.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Andrew Dudum sold 660,000 shares of the business’s stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $50.58, for a total value of $33,382,800.00. Following the transaction, the chief executive officer owned 2,214,769 shares of the company’s stock, valued at approximately $112,023,016.02. The trade was a 22.96% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,622,741 shares of company stock worth $83,695,469 in the last quarter. 13.71% of the stock is owned by company insiders.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock opened at $53.98 on Friday. The stock has a market cap of $12.20 billion, a price-to-earnings ratio of 67.48, a price-to-earnings-growth ratio of 3.64 and a beta of 2.25. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. The stock has a 50 day moving average price of $50.86 and a 200-day moving average price of $48.00. Hims & Hers Health, Inc. has a one year low of $17.36 and a one year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company had revenue of $544.83 million during the quarter, compared to analysts’ expectations of $550.06 million. During the same quarter last year, the firm posted $0.06 EPS. Hims & Hers Health’s revenue for the quarter was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Citigroup restated a “sell” rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Zacks Research cut Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Truist Financial cut their price target on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a report on Monday, August 18th. UBS Group set a $30.00 price target on Hims & Hers Health in a report on Monday, June 23rd. Finally, Canaccord Genuity Group restated a “buy” rating and set a $68.00 price target on shares of Hims & Hers Health in a report on Friday, September 12th. Two investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average target price of $38.92.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.